Cover Image
市場調查報告書

AbbVie Inc.- 產品平台檢討

AbbVie Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 293993
出版日期 內容資訊 英文 204 Pages
訂單完成後即時交付
價格
Back to Top
AbbVie Inc.- 產品平台檢討 AbbVie Inc. - Product Pipeline Review - 2016
出版日期: 2016年03月30日 內容資訊: 英文 204 Pages
簡介

AbbVie Inc.是總公司設置於美國的研究開發型生物製藥企業。從事複合疾病及嚴重疾病之先進治療藥的研究開發、製造及商品化。其產品用於克隆氏症,囊狀纖維化症的併發症,HIV,帕金森氏症,類風濕性關節炎,乾癬,甲狀腺相關疾病,潰瘍性結腸炎,慢性腎臟病併發症等疾病的治療上。

本報告提供AbbVie Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

AbbVie Inc.的基本資料

  • AbbVie Inc.概要
  • 主要資訊
  • 企業資料

AbbVie Inc.:R&D概要

  • 主要的治療範圍

AbbVie Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

AbbVie Inc.:開發中產品概況

  • 後期階段產品開發中產品
  • 臨床階段的開發中產品
  • 初期階段的開發中產品

AbbVie Inc.:藥物簡介

  • (ombitasvir + paritaprevir + ritonavir)
  • adalimumab
  • daclizumab
  • (carbidopa + levodopa)
  • atrasentan hydrochloride
  • elagolix sodium
  • elotuzumab
  • fluvoxamine maleate
  • ombitasvir
  • paricalcitol
  • paritaprevir
  • veliparib
  • venetoclax
  • ABT-122
  • ABT-414
  • ABT-436
  • ABT-493
  • ABT-493 + ABT-530
  • ABT-494
  • ABT-530
  • ABT-806
  • ABT-981
  • navitoclax dihydrochloride
  • ABBV-075
  • ABBV-084
  • ABBV-221
  • ABBV-399
  • ABBV-672
  • ABT-165
  • ABT-257
  • ABT-354
  • ABT-700
  • ABT-767
  • ABT-957
  • Antibody Drug Conjugate to Inhibit EFGR for Squamous Cell Tumor and Glioblastoma
  • ilorasertib
  • A-1048400
  • A-1264087
  • A-431404
  • A-705253
  • A-801195
  • A-889425
  • A-918446
  • ABT-487
  • ABT-731
  • ABT-737
  • ABT-898
  • Antisense Gene Therapy to Inhibit Aldehyde Dehydrogenase for Alcoholism
  • APG-880
  • Monoclonal Antibodies to Inhibit Tau for Alzheimer's Disease and Tauopathies
  • Monoclonal Antibody Conjugates for Cancer
  • SLV-330
  • Small Molecule to Inhibit PKC Theta for Autoimmune Disease
  • Small Molecules to Antagonize GnRH for Women's Health, BPH and Oncology
  • SOL-1
  • Monoclonal Antibodies for Chronic Pain
  • Small Molecules to Inhibit CDPK1 for Protozoal Infections
  • Small Molecules to Inhibit MCL-1 for Cancer
  • AbbVie Inc. - Pipeline Analysis

AbbVie Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AbbVie Inc.:最新的開發平台資訊

AbbVie Inc.:開發暫停中的計劃

AbbVie Inc.:開發中止的開發中產品

AbbVie Inc.:企業理念

AbbVie Inc.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08005CDB

Summary

Global Markets Direct's, 'AbbVie Inc. - Product Pipeline Review - 2016', provides an overview of the AbbVie Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AbbVie Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of AbbVie Inc.
  • The report provides overview of AbbVie Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses AbbVie Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features AbbVie Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate AbbVie Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for AbbVie Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding AbbVie Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AbbVie Inc. Snapshot
    • AbbVie Inc. Overview
    • Key Information
    • Key Facts
  • AbbVie Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • AbbVie Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • AbbVie Inc. - Pipeline Products Glance
  • AbbVie Inc. - Late Stage Pipeline Products
  • AbbVie Inc. - Clinical Stage Pipeline Products
  • AbbVie Inc. - Early Stage Pipeline Products
  • AbbVie Inc. - Drug Profiles
    • adalimumab
    • daclizumab
    • elotuzumab
    • ibrutinib
    • venetoclax
    • Viekira-3QD
    • (ombitasvir + paritaprevir + ritonavir) + dasabuvir
    • atrasentan hydrochloride
    • elagolix sodium
    • fluvoxamine maleate
    • glecaprevir
    • glecaprevir + pibrentasvir
    • ombitasvir
    • paricalcitol
    • paritaprevir
    • pibrentasvir
    • upadacitinib tartrate
    • veliparib
    • depatuxizumab mafodotin
    • ABT-122
    • ABT-436
    • ABT-981
    • depatuxizumab
    • navitoclax dihydrochloride
    • ABBV-075
    • ABBV-084
    • ABBV-085
    • ABBV-221
    • ABBV-672
    • ABBV-838
    • ABBV-8E12
    • ABT-165
    • ABT-257
    • ABT-399
    • ABT-555
    • ABT-700
    • ABT-767
    • ABT-957
    • ilorasertib
    • A-1048400
    • A-1262543
    • A-1264087
    • A-431404
    • A-705253
    • A-889425
    • A-988315
    • ABT-207
    • ABT-737
    • APG-880
    • Biologics for Undisclosed Indication
    • h-5F9AM8
    • Monoclonal Antibodies to Inhibit RGMa for Multiple Sclerosis
    • Monoclonal Antibody Conjugates for Oncology
    • Small Molecule to Inhibit PKC Theta for Autoimmune Disease
    • Small Molecule to Inhibit WEE-1 for Oncology
    • Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology
    • SOL-1
    • A-893
    • Monoclonal Antibodies for Chronic Pain
    • Small Molecules to Inhibit CDPK1 for Protozoal Infections
    • Small Molecules to Inhibit Jak1 for Undisclosed Indication
    • Small Molecules to Inhibit MCL-1 for Cancer
  • AbbVie Inc. - Pipeline Analysis
    • AbbVie Inc. - Pipeline Products by Target
    • AbbVie Inc. - Pipeline Products by Route of Administration
    • AbbVie Inc. - Pipeline Products by Molecule Type
    • AbbVie Inc. - Pipeline Products by Mechanism of Action
  • AbbVie Inc. - Recent Pipeline Updates
  • AbbVie Inc. - Dormant Projects
  • AbbVie Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • AbbVie Inc. - Company Statement
  • AbbVie Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AbbVie Inc., Key Information
  • AbbVie Inc., Key Facts
  • AbbVie Inc. - Pipeline by Indication, 2016
  • AbbVie Inc. - Pipeline by Stage of Development, 2016
  • AbbVie Inc. - Monotherapy Products in Pipeline, 2016
  • AbbVie Inc. - Combination Treatment Modalities in Pipeline, 2016
  • AbbVie Inc. - Partnered Products in Pipeline, 2016
  • AbbVie Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • AbbVie Inc. - Out-Licensed Products in Pipeline, 2016
  • AbbVie Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • AbbVie Inc. - Pre-Registration, 2016
  • AbbVie Inc. - Filing rejected/Withdrawn, 2016
  • AbbVie Inc. - Phase III, 2016
  • AbbVie Inc. - Phase II, 2016
  • AbbVie Inc. - Phase I, 2016
  • AbbVie Inc. - Preclinical, 2016
  • AbbVie Inc. - Discovery, 2016
  • AbbVie Inc. - Pipeline by Target, 2016
  • AbbVie Inc. - Pipeline by Route of Administration, 2016
  • AbbVie Inc. - Pipeline by Molecule Type, 2016
  • AbbVie Inc. - Pipeline Products by Mechanism of Action, 2016
  • AbbVie Inc. - Recent Pipeline Updates, 2016
  • AbbVie Inc. - Dormant Developmental Projects,2016
  • AbbVie Inc. - Discontinued Pipeline Products, 2016
  • AbbVie Inc., Subsidiaries

List of Figures

  • AbbVie Inc. - Pipeline by Top 10 Indication, 2016
  • AbbVie Inc. - Pipeline by Stage of Development, 2016
  • AbbVie Inc. - Monotherapy Products in Pipeline, 2016
  • AbbVie Inc. - Partnered Products in Pipeline, 2016
  • AbbVie Inc. - Pipeline by Top 10 Target, 2016
  • AbbVie Inc. - Pipeline by Route of Administration, 2016
  • AbbVie Inc. - Pipeline by Molecule Type, 2016
  • AbbVie Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top